search
Back to results

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (KRAKEN)

Primary Purpose

Lipoprotein Disorder

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LY3473329
Placebo
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lipoprotein Disorder focused on measuring Atherosclerotic cardiovascular disease, ASCVD, Dyslipidemia, Lipoprotein(a), Lp(a), Cardiovascular, Cardiovascular disease, Cholesterol, Hyperlipidemia

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants must be at least 40 years old
  • Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory.
  • High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atherosclerotic cardiovascular disease (ASCVD) risk equivalents (familial hypercholesterolemia or type 2 diabetes).

  • Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period.

    • lipid-lowering drugs
    • testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone
  • Have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive.
  • Males who agree to use highly effective or effective methods of contraception may participate in this trial.
  • Women of childbearing potential (WOCBP) who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial.

Exclusion Criteria:

  • Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.

  • Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:

    • major surgery
    • coronary, carotid, or peripheral arterial revascularization
    • stroke or transient ischemic attack
    • myocardial infarction or unstable angina
    • acute limb ischemia
  • Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes
  • Have uncontrolled hypertension

Sites / Locations

  • Care Access - BaltimoreRecruiting
  • Care Access - DorchesterRecruiting
  • Care Access - LimaRecruiting
  • Core Research GroupRecruiting
  • Royal Adelaide HospitalRecruiting
  • Nightingale ResearchRecruiting
  • Victorian Heart HospitalRecruiting
  • CEDOESRecruiting
  • Pesquisa Clínica em Diabetes - Dra Rosângela RéaRecruiting
  • CPCLINRecruiting
  • Centro de Pesquisa Clinica do CoracaoRecruiting
  • Incor - Instituto do CoracaoRecruiting
  • IBPClin - Instituto Brasil de Pesquisa ClínicaRecruiting
  • Instituto Dante Pazzanese de CardiologyRecruiting
  • Hospital das Clinicas FMUSPRecruiting
  • Third People's Hospital of Hainan ProvinceRecruiting
  • The First Hospital of Harbin Medical UniversityRecruiting
  • The Fourth Hospital of Harbin Medical UniversityRecruiting
  • Changzhou Second People's HospitalRecruiting
  • The Second Affiliated Hospital of Nanjing Medical UniversityRecruiting
  • The Third Hospital of NanchangRecruiting
  • China-Japan Union HospitalRecruiting
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityRecruiting
  • Gemeinschaftpraxis Dr. med. Martin Prohaska und Dr. med. Felix SchulteRecruiting
  • ClinPhenomics GmbH & Co KGRecruiting
  • Kath. St.-Johannes-Gesellschaft DortmundRecruiting
  • Private Practice - Dr. Frank MenzelRecruiting
  • Onkoradiologiai KozpontRecruiting
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai KözpontRecruiting
  • Medifarma 98 KftRecruiting
  • Flor Ferenc Hospital of Pest CountyRecruiting
  • Belvárosi EgészségházRecruiting
  • Dél-Pesti CentrumkórházRecruiting
  • Semmelweis UniversityRecruiting
  • Funabashi Municipal Medical CenterRecruiting
  • Kokura Memorial HospitalRecruiting
  • Iwate Prefectural Central HospitalRecruiting
  • Medical Corporation Heishinkai OCROM ClinicRecruiting
  • Minamino Cardiovascular HospitalRecruiting
  • Hiroshima City HospitalRecruiting
  • Miyazaki Medical Association HospitalRecruiting
  • VieCuri Medisch Centrum, locatie VenloRecruiting
  • Meander Medisch CentrumRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

LY3473329 Dose 1

LY3473329 Dose 2

LY3473329 Dose 3

Placebo

Arm Description

Participants will receive LY3473329 orally.

Participants will receive LY3473329 orally.

Participants will receive LY3473329 orally.

Participants will receive placebo orally.

Outcomes

Primary Outcome Measures

Percent Change from Baseline in Lipoprotein (a) Lp(a)

Secondary Outcome Measures

Percentage of Participants Achieving Lp(a) <125 Nanomole/Liter (nmol/L)
Percent Change from Baseline for Apolipoprotein B (ApoB)
Percent Change from Baseline for High Sensitivity C-reactive (hsCRP)
Pharmacokinetics (PK): Trough Concentrations (Ctrough) of LY3473329
PK Ctrough of LY34723329 will be measured

Full Information

First Posted
September 28, 2022
Last Updated
October 20, 2023
Sponsor
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT05563246
Brief Title
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Acronym
KRAKEN
Official Title
KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 24, 2022 (Actual)
Primary Completion Date
January 8, 2024 (Anticipated)
Study Completion Date
January 8, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lipoprotein Disorder
Keywords
Atherosclerotic cardiovascular disease, ASCVD, Dyslipidemia, Lipoprotein(a), Lp(a), Cardiovascular, Cardiovascular disease, Cholesterol, Hyperlipidemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
233 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LY3473329 Dose 1
Arm Type
Experimental
Arm Description
Participants will receive LY3473329 orally.
Arm Title
LY3473329 Dose 2
Arm Type
Experimental
Arm Description
Participants will receive LY3473329 orally.
Arm Title
LY3473329 Dose 3
Arm Type
Experimental
Arm Description
Participants will receive LY3473329 orally.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive placebo orally.
Intervention Type
Drug
Intervention Name(s)
LY3473329
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered orally
Primary Outcome Measure Information:
Title
Percent Change from Baseline in Lipoprotein (a) Lp(a)
Time Frame
Baseline to Week 12
Secondary Outcome Measure Information:
Title
Percentage of Participants Achieving Lp(a) <125 Nanomole/Liter (nmol/L)
Time Frame
Week 12
Title
Percent Change from Baseline for Apolipoprotein B (ApoB)
Time Frame
Baseline, Week 12
Title
Percent Change from Baseline for High Sensitivity C-reactive (hsCRP)
Time Frame
Baseline, Week 12
Title
Pharmacokinetics (PK): Trough Concentrations (Ctrough) of LY3473329
Description
PK Ctrough of LY34723329 will be measured
Time Frame
Baseline to Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must be at least 40 years old Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory. High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atherosclerotic cardiovascular disease (ASCVD) risk equivalents (familial hypercholesterolemia or type 2 diabetes). Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period. lipid-lowering drugs testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone Have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive. Males who agree to use highly effective or effective methods of contraception may participate in this trial. Women of childbearing potential (WOCBP) who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial. Exclusion Criteria: Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data. Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization: major surgery coronary, carotid, or peripheral arterial revascularization stroke or transient ischemic attack myocardial infarction or unstable angina acute limb ischemia Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes Have uncontrolled hypertension
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone
1-317-615-4559
Email
ClinicalTrials.gov@lilly.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Care Access - Baltimore
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ali Bajwa
Facility Name
Care Access - Dorchester
City
Dorchester
State/Province
Massachusetts
ZIP/Postal Code
02124
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peta-Gay Jackson Booth
Facility Name
Care Access - Lima
City
Lima
State/Province
Ohio
ZIP/Postal Code
45805
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ali Bajwa
Facility Name
Core Research Group
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4064
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
Phone
61738765688
First Name & Middle Initial & Last Name & Degree
David Martin Colquhoun
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter James Psaltis
Facility Name
Nightingale Research
City
Adelaide
State/Province
South Aust
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Hamilton
Facility Name
Victorian Heart Hospital
City
Clayton
State/Province
Victoria
ZIP/Postal Code
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Nicholls
Facility Name
CEDOES
City
Vitória
State/Province
Espírito Santo
ZIP/Postal Code
29055450
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
2721250215
First Name & Middle Initial & Last Name & Degree
Fernando Torres Gomes
Facility Name
Pesquisa Clínica em Diabetes - Dra Rosângela Réa
City
Curitiba
State/Province
Paraná
ZIP/Postal Code
80040-110
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
554133629778
First Name & Middle Initial & Last Name & Degree
Rodrigo Julio Cerci
Facility Name
CPCLIN
City
Natal
State/Province
Rio Grande Do Norte
ZIP/Postal Code
59025-050
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
551127110298
First Name & Middle Initial & Last Name & Degree
Freddy Goldberg Eliaschewitz
Facility Name
Centro de Pesquisa Clinica do Coracao
City
Acaraju
State/Province
Sergipe
ZIP/Postal Code
49055-530
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
5579999870794
First Name & Middle Initial & Last Name & Degree
FÁBIO SERRA SILVEIRA
Facility Name
Incor - Instituto do Coracao
City
Sao Paulo
State/Province
São Paulo
ZIP/Postal Code
05403-900
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
551126615320
First Name & Middle Initial & Last Name & Degree
Raul Santos
Facility Name
IBPClin - Instituto Brasil de Pesquisa Clínica
City
Rio de Janeiro
ZIP/Postal Code
20241-180
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
552125277979
First Name & Middle Initial & Last Name & Degree
JOSELITA FRANÇA DE SIQUEIRA BODART
Facility Name
Instituto Dante Pazzanese de Cardiology
City
São Paulo
ZIP/Postal Code
04012-909
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
1150856204
First Name & Middle Initial & Last Name & Degree
Andre Arpad Faludi
Facility Name
Hospital das Clinicas FMUSP
City
São Paulo
ZIP/Postal Code
04266-010
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
Phone
551122713450
First Name & Middle Initial & Last Name & Degree
Breno Balabem Alves
Facility Name
Third People's Hospital of Hainan Province
City
Sanya
State/Province
Hainan
ZIP/Postal Code
572000
Country
China
Individual Site Status
Recruiting
Facility Contact:
Phone
089838220198
First Name & Middle Initial & Last Name & Degree
Ling Lin
Facility Name
The First Hospital of Harbin Medical University
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lu Fu
Facility Name
The Fourth Hospital of Harbin Medical University
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ZhiFeng Cheng
Facility Name
Changzhou Second People's Hospital
City
Changzhou
State/Province
Jiangsu
ZIP/Postal Code
213000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuan Ji
Facility Name
The Second Affiliated Hospital of Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210011
Country
China
Individual Site Status
Recruiting
Facility Contact:
Phone
17768136543
First Name & Middle Initial & Last Name & Degree
Mingzhi Long
Facility Name
The Third Hospital of Nanchang
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330009
Country
China
Individual Site Status
Recruiting
Facility Contact:
Phone
15179192775
First Name & Middle Initial & Last Name & Degree
Zhaohui Pei
Facility Name
China-Japan Union Hospital
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130033
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuquan He
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710061
Country
China
Individual Site Status
Recruiting
Facility Contact:
Phone
862985323819
First Name & Middle Initial & Last Name & Degree
Zuyi Yuan
Facility Name
Gemeinschaftpraxis Dr. med. Martin Prohaska und Dr. med. Felix Schulte
City
Mühldorf
State/Province
Bayern
ZIP/Postal Code
84453
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
004986311849092
First Name & Middle Initial & Last Name & Degree
Martin Wolfgang Prohaska
Facility Name
ClinPhenomics GmbH & Co KG
City
Frankfurt
State/Province
Hessen
ZIP/Postal Code
60596
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
49069577028
First Name & Middle Initial & Last Name & Degree
Bernhard Rudolf Winkelmann
Facility Name
Kath. St.-Johannes-Gesellschaft Dortmund
City
Dortmund
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
44137
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
49231184335
First Name & Middle Initial & Last Name & Degree
Helge Möllmann
Facility Name
Private Practice - Dr. Frank Menzel
City
Dessau
ZIP/Postal Code
06846
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
00493406612850
First Name & Middle Initial & Last Name & Degree
Frank Menzel
Facility Name
Onkoradiologiai Kozpont
City
Kecskemét
State/Province
Bács-Kiskun
ZIP/Postal Code
6000
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andras Nagy
Facility Name
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
City
Szeged
State/Province
Csongrád
ZIP/Postal Code
6720
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
Phone
3662545553
First Name & Middle Initial & Last Name & Degree
Albert Varga
Facility Name
Medifarma 98 Kft
City
Nyiregyhaza
State/Province
Nyíregyháza
ZIP/Postal Code
4400
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
Phone
06209530430
First Name & Middle Initial & Last Name & Degree
Zsolt Zilahi
Facility Name
Flor Ferenc Hospital of Pest County
City
Kistarcsa
State/Province
Pest
ZIP/Postal Code
2143
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
Phone
28507600
First Name & Middle Initial & Last Name & Degree
Robert J. Kirschner
Facility Name
Belvárosi Egészségház
City
Zalaegerszeg
State/Province
Zala
ZIP/Postal Code
8900
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
Phone
3692507500
First Name & Middle Initial & Last Name & Degree
Geza Lupkovics
Facility Name
Dél-Pesti Centrumkórház
City
Budapest
ZIP/Postal Code
1097
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
Phone
0036309343629
First Name & Middle Initial & Last Name & Degree
Andras R Vertes
Facility Name
Semmelweis University
City
Budapest
ZIP/Postal Code
1536
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
Phone
3614586840
First Name & Middle Initial & Last Name & Degree
Béla Merkely
Facility Name
Funabashi Municipal Medical Center
City
Funabashi
State/Province
Chiba
ZIP/Postal Code
273-0853
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
shigeru fukuzawa
Facility Name
Kokura Memorial Hospital
City
Kitakyushu
State/Province
Fukuoka
ZIP/Postal Code
802-8555
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kenji Ando
Facility Name
Iwate Prefectural Central Hospital
City
Morioka
State/Province
Iwate
ZIP/Postal Code
020-0066
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
81196531151
First Name & Middle Initial & Last Name & Degree
Akihiro Nakamura
Facility Name
Medical Corporation Heishinkai OCROM Clinic
City
Suita-shi
State/Province
Osaka
ZIP/Postal Code
565-0853
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
0663308810
First Name & Middle Initial & Last Name & Degree
Satoshi Inoue
Facility Name
Minamino Cardiovascular Hospital
City
Hachioji
State/Province
Tokyo
ZIP/Postal Code
192-0918
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yoshiki Hata
Facility Name
Hiroshima City Hospital
City
Hiroshima
ZIP/Postal Code
730-8518
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nobuo Shiode
Facility Name
Miyazaki Medical Association Hospital
City
Miyazaki
ZIP/Postal Code
880-2102
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yoshisato Shibata
Facility Name
VieCuri Medisch Centrum, locatie Venlo
City
Venlo
State/Province
Limburg
ZIP/Postal Code
5912 BL
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
31773205603
First Name & Middle Initial & Last Name & Degree
Roland Troquay
Facility Name
Meander Medisch Centrum
City
Amersfoort
State/Province
Utrecht
ZIP/Postal Code
3813 TZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
31338501122
First Name & Middle Initial & Last Name & Degree
Lioe-Ting Dijkhorst-Oei

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing URL
http://vivli.org/
Links:
URL
https://trials.lilly.com/en-US/trial/362835
Description
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (KRAKEN)

Learn more about this trial

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

We'll reach out to this number within 24 hrs